BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 9817290)

  • 1. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.
    Bradshaw DM; Arceci RJ
    J Clin Oncol; 1998 Nov; 16(11):3674-90. PubMed ID: 9817290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-P-glycoprotein drug export mechanisms of multidrug resistance.
    List AF
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):20-4. PubMed ID: 9408957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance.
    Muñoz-Martínez F; Lu P; Cortés-Selva F; Pérez-Victoria JM; Jiménez IA; Ravelo AG; Sharom FJ; Gamarro F; Castanys S
    Cancer Res; 2004 Oct; 64(19):7130-8. PubMed ID: 15466210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
    Modok S; Mellor HR; Callaghan R
    Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversing agents for ATP-binding cassette drug transporters.
    Lee CH
    Methods Mol Biol; 2010; 596():325-40. PubMed ID: 19949930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia.
    Swerts K; De Moerloose B; Dhooge C; Laureys G; Benoit Y; Philippé J
    Eur J Cancer; 2006 Feb; 42(3):295-309. PubMed ID: 16324833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and pharmacological strategies to overcome multidrug resistance.
    Shabbits JA; Krishna R; Mayer LD
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):585-94. PubMed ID: 12113091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of multidrug resistance in the age of targeted therapy.
    Türk D; Szakács G
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.
    Mo L; Pospichalova V; Huang Z; Murphy SK; Payne S; Wang F; Kennedy M; Cianciolo GJ; Bryja V; Pizzo SV; Bachelder RE
    PLoS One; 2015; 10(7):e0131579. PubMed ID: 26148191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug retention, efflux, and resistance in tumor cells.
    Krishan A; Fitz CM; Andritsch I
    Cytometry; 1997 Dec; 29(4):279-85. PubMed ID: 9415409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multidrug resistance of cancer cells mediated by ABC superfamily transporters].
    Ueda K
    Nihon Rinsho; 1997 May; 55(5):1024-9. PubMed ID: 9155147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it.
    Hait WN; Yang JM
    Semin Oncol; 2005 Dec; 32(6 Suppl 7):S16-21. PubMed ID: 16360718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer].
    Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Keshari RP; Zhang LY
    Ai Zheng; 2009 Apr; 28(4):337-43. PubMed ID: 19622290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of ATP-binding cassette transporters and clinical implications.
    Cascorbi I; Haenisch S
    Methods Mol Biol; 2010; 596():95-121. PubMed ID: 19949922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microparticles and their emerging role in cancer multidrug resistance.
    Gong J; Jaiswal R; Mathys JM; Combes V; Grau GE; Bebawy M
    Cancer Treat Rev; 2012 May; 38(3):226-34. PubMed ID: 21757296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines.
    Cuestas ML; Sosnik A; Mathet VL
    Mol Pharm; 2011 Aug; 8(4):1152-64. PubMed ID: 21591727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Structures and functions of xenobiotic efflux pump P-glycoprotein and MRP--important molecular targets for cancer chemotherapy].
    Ueda K
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2190-5. PubMed ID: 9422060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.